Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity:: Role of 5-HT1B/1D and 5-HT2 receptors

被引:86
作者
Bankson, MG [1 ]
Cunningham, KA [1 ]
机构
[1] Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA
关键词
5-HT1B receptors; 5-HT2A receptors; 5-HT2C receptors; M100907; MDL; 100907; MDMA; 3,4-methylenedioxymethamphetamine; SB; 206553; serotonin;
D O I
10.1016/S0893-133X(01)00345-1
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The role of serotonin 5-HT2 receptors (5-HT2R) in the hyperactivity induced by (+)-3,4-methylenedioxy-methamphetamine ((+)-MDMA; 3 mg/kg) was investigated. Hyperactivity induced by (+)-MDMA was robustly potentiated by the 5-HT2B/2CR antagonist SB 206553 (1.0,2.0, and 4.0 mg/kg). Administration of the 5-HT1B/1DR antagonist GR 127935 (2.5 mg/kg) or the 5-HT2AR antagonist M100907 (1.0 mg/kg) partially suppressed the potentiated hyperactivity seenfollowing SB 206553 plus (+)-MDMA; a blockade to activity levels seen with (+)-MDMA alone was observed following the combination of GR 127935 plus M100907. A modest potentiative interaction was seen when SB 206553 was combined with the DA releaser amphetamine (0.5 mg/kg) or amphetamine plus the 5-HT releaser fenfluramine (4.0 mg/kg). SB 206553 (1-4 mg/kg), GR 127935 (2.5 mg/kg) and M100907 (1 mg/kg) did not alter spontaneous activity upon administration singly or in combination. These data suggest that activation of 5-HT2CR exerts a strong inhibitory influence on the hyperactivity induced by (+)-MDMA, and that 5-HT2CR blockade unmasks hyperactivity mediated through several mechanisms. [Neuropsychopharmacology 26:40-52,2002] (C) 2001 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.
引用
收藏
页码:40 / 52
页数:13
相关论文
共 60 条
[1]  
AULAKH CS, 1988, PSYCHOPHARMACOLOGY, V95, P313
[2]  
Bankson MG, 2001, J PHARMACOL EXP THER, V297, P846
[3]   A review of central 5-HT receptors and their function [J].
Barnes, NM ;
Sharp, T .
NEUROPHARMACOLOGY, 1999, 38 (08) :1083-1152
[4]   PHARMACOLOGIC PROFILE OF MDMA (3,4-METHYLENEDIOXYMETHAMPHETAMINE) AT VARIOUS BRAIN RECOGNITION SITES [J].
BATTAGLIA, G ;
BROOKS, BP ;
KULSAKDINUN, C ;
DESOUZA, EB .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 149 (1-2) :159-163
[5]  
BENLOUCIF S, 1993, J PHARMACOL EXP THER, V265, P373
[6]  
CALLAHAN PM, 1995, J PHARMACOL EXP THER, V274, P1414
[7]  
CALLAWAY CW, 1992, NEUROPSYCHOPHARMACOL, V7, P113
[8]  
CALLAWAY CW, 1990, J PHARMACOL EXP THER, V254, P456
[9]   SUPPRESSION OF BEHAVIORAL ACTIVITY BY NORFENFLURAMINE AND RELATED DRUGS IN RATS IS NOT MEDIATED BY SEROTONIN RELEASE [J].
CALLAWAY, CW ;
WING, LL ;
NICHOLS, DE ;
GEYER, MA .
PSYCHOPHARMACOLOGY, 1993, 111 (02) :169-178
[10]   Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS [J].
Clemett, DA ;
Punhani, T ;
Duxon, MS ;
Blackburn, TP ;
Fone, KCF .
NEUROPHARMACOLOGY, 2000, 39 (01) :123-132